Managing Vaccination Campaigns

Managing Vaccination Campaigns

Why This Skill Exists

Mass vaccination campaigns are among the most logistically complex and high-impact operations in public health. Whether responding to a pandemic (COVID-19 mRNA vaccine rollout), controlling an outbreak (ring vaccination for mpox or Ebola), or executing a routine seasonal campaign (influenza), success depends on cold chain integrity, equitable allocation, trained workforce deployment, adverse event monitoring through VAERS and V-safe, and real-time coverage tracking through IIS (Immunization Information Systems). Errors in any of these domains waste scarce vaccine supply, erode public trust, or miss vulnerable populations. This skill codifies the operational framework used by CDC's Immunization Services Division, ACIP recommendations, and state/local immunization programs.

Checkpoint A — Intake and Scoping

Intake Questions

1. What vaccine product(s) will be administered? (Manufacturer, formulation, dose schedule, age indications per current ACIP recommendations.)
2. Is this a routine campaign (seasonal influenza), catch-up campaign (childhood immunization), or emergency/outbreak response?
3. What is the target population — entire jurisdiction, specific age group, high-risk group, healthcare workers, or congregate setting residents?
4. What is the target coverage rate? (Healthy People 2030 targets: 70% influenza for adults 18+; 90% childhood series completion by age 2.)
5. What is the current vaccine supply — doses on hand, allocation expected, and from which distributor (CDC direct, state depot, commercial)?
6. What cold chain infrastructure exists — ultra-cold (-80°C to -60°C), frozen (-25°C to -15°C), refrigerated (2°C to 8°C)?
7. What is the IIS (state immunization registry) and how will doses be reported?
8. What is the jurisdiction's VAERS/V-safe adverse event reporting protocol?

Required Documents

• Current ACIP recommendations and clinical considerations for the vaccine product(s)
• Vaccine storage and handling toolkit (CDC)
• Emergency Use Authorization (EUA) fact sheets (if applicable)
• State/local immunization program plan and allocation framework
• Standing orders or prescriptive authority documentation for vaccine administration
• IIS data-entry SOPs and interface specifications
• VAERS reporting forms and clinically important adverse event definitions
• Community engagement plan for vaccine confidence and equity

Step 1 — Plan Allocation and Prioritization

• Apply the jurisdiction's allocation framework, which should align with ACIP prioritization tiers (e.g., Phase 1a/1b/1c for pandemic vaccines) or NVAC ethical framework principles: maximize benefits, mitigate health inequities, promote justice, and ensure transparency.
• Calculate doses needed: target population size × number of doses in the series × (1 + wastage factor). Standard wastage factors: 5% for single-dose vials, up to 15% for multi-dose vials.
• Identify priority populations with documented disparities in coverage (use IIS data stratified by race/ethnicity, zip code, insurance status). Allocate proportionally more resources to underserved communities.
• Establish allocation tiers and transition triggers (e.g., move from Phase 1b to Phase 2 when 70% of Phase 1b eligible have received dose 1 or supply exceeds demand at current tier).
• Develop a contingency plan for supply interruptions: identify buffer stock thresholds, alternative distribution channels, and communication protocols for rescheduling appointments when supply is constrained.
• Document allocation rationale and decision criteria in a publicly accessible format to maintain transparency and satisfy ethics review requirements.
• Coordinate with neighboring jurisdictions to align tier transitions and prevent vaccine tourism or cross-border inequities.
• Maintain a priority population registry with contact information to enable proactive outreach when new tiers open or booster recommendations change.

Step 2 — Establish Vaccination Sites and Cold Chain

• Site selection criteria: geographic accessibility for target population, ADA compliance, adequate space for throughput (flow: registration → screening → administration → observation → exit), proximity to emergency medical services, and cultural appropriateness.
• Site types: fixed clinics (health department, pharmacy, hospital), mobile units (vans, pop-up tents), drive-through, homebound/in-home administration, employer/school-based.
• Cold chain management per CDC Vaccine Storage and Handling Toolkit:
  • Use calibrated digital data loggers (DDL) with Certificate of Calibration Testing (not food-grade thermometers).
  • Monitor temperatures continuously and log twice daily at minimum.
  • Maintain emergency plan for equipment failure: backup generator, qualified transport containers, emergency contacts.
  • For ultra-cold products: thermal shippers with dry ice, strict monitoring of replenishment schedule.
• Vaccine inventory management: track lot numbers, expiration dates, doses drawn per vial, and wastage. Report through VTrckS or state equivalent.

Step 3 — Administer Vaccines with Standardized Protocols

• Implement standing orders per ACIP that authorize vaccine administration without individual physician orders. Standing orders must specify: vaccine product, dose, route, site, contraindications, precautions, and screening questions.
• Pre-vaccination screening: use CDC's Screening Checklist for Contraindications (separate forms for adults, children, and specific vaccines). Screen for: age eligibility, prior doses, contraindications (anaphylaxis to vaccine component), precautions (moderate/severe illness), and pregnancy status.
• For pediatric populations, verify age-appropriate formulations and dosing volumes. Confirm the series schedule (e.g., 2-dose vs. 3-dose) and minimum intervals between doses per ACIP catch-up schedule.
• Administer vaccine per manufacturer instructions (IM injection for most; SC for specific products; intranasal for LAIV). Observe needle length and site selection by age and body habitus.
• When administering multiple vaccines simultaneously, use separate anatomical sites with at least 1 inch separation. Document exact site (e.g., left deltoid, right anterolateral thigh) for each product.
• Post-vaccination observation: minimum 15 minutes for standard recipients; 30 minutes for those with history of anaphylaxis or syncope. Have epinephrine auto-injectors and anaphylaxis protocol at every site.
• Ensure every vaccination station has a visible emergency protocol poster and staff have rehearsed anaphylaxis response within the prior 90 days.
• Document administration immediately in the IIS: patient demographics, vaccine product, manufacturer, lot number, expiration date, administration date, site, route, administering provider, and VIS (Vaccine Information Statement) date provided.
• Provide each vaccinee with a vaccination record card (CDC COVID-19 Vaccination Record Card or equivalent) containing product, lot number, date, and site of administration.

Step 4 — Monitor Adverse Events and Safety Signals

• Report all clinically significant adverse events to VAERS (Vaccine Adverse Event Reporting System). Healthcare providers are mandated reporters for events listed in the VAERS Table of Reportable Events (e.g., anaphylaxis, Guillain-Barré syndrome, death following vaccination).
• For vaccines under EUA, report all vaccination errors (even without adverse events) and all serious adverse events to VAERS.
• If V-safe (CDC smartphone-based monitoring) is active for the product, enroll vaccinees and monitor check-in data for safety signals.
• Track adverse event rates at the jurisdiction level: anaphylaxis rate (expected: ~2-5 per million doses for mRNA COVID-19 vaccines), syncope rate, and injection-site reaction rates.
• Participate in Vaccine Safety Datalink (VSD) or CISA (Clinical Immunization Safety Assessment) referral processes for complex cases.

Step 5 — Track Coverage, Equity, and Campaign Performance

• Generate weekly coverage reports from IIS data stratified by: age group, race/ethnicity, geography (zip code or census tract), insurance status, and provider type.
• Calculate coverage rate = (persons with ≥1 dose or completed series) / (target population) × 100.
• Monitor equity metrics: coverage ratio between highest- and lowest-covered racial/ethnic groups (target: ratio ≤ 1.2 indicating near-equitable coverage).
• Track operational metrics: doses administered per site per day, no-show rate for scheduled appointments, second-dose completion rate (for multi-dose series), wastage rate (target: < 5%).
• Adjust campaign strategy based on data: redeploy mobile units to low-coverage areas, extend hours at high-demand sites, activate trusted messengers for vaccine-hesitant communities.
• Report coverage data to CDC through IIS and jurisdiction immunization program reports.

Checkpoint B — Campaign Review

• ACIP recommendations followed for product selection, dosing, and prioritization
• Cold chain maintained with documented temperature logs and no excursions (or excursions investigated per CDC protocol)
• Standing orders current and signed by authorized prescriber
• All administered doses recorded in IIS within 24 hours of administration
• VAERS reports filed for all reportable adverse events
• Coverage data stratified by demographics and geography to assess equity
• Wastage rates calculated and within acceptable range
• Community engagement activities documented with reach metrics

Quality Audit

• Vaccine products stored within manufacturer-specified temperature ranges with continuous DDL monitoring
• Lot numbers traceable from receipt through administration for every dose
• Pre-vaccination screening checklist completed for every vaccinee
• VIS provided and documented for every vaccine administered (National Childhood Vaccine Injury Act requirement)
• Observation periods met (15 or 30 minutes) with anaphylaxis kit accessible at every station
• IIS data quality: < 5% records with missing required fields (DOB, vaccine product, lot number)
• Equity dashboard reviewed weekly by program leadership with action items documented
• All campaign staff completed CDC "You Call the Shots" or equivalent immunization training modules
• Wastage rate calculated per site per week and compared against acceptable thresholds (< 5% single-dose, < 15% multi-dose)
• Second-dose appointment scheduling and reminder systems operational for multi-dose series
• Emergency medical equipment inspected and restocked at every vaccination site before each session
• Standing orders reviewed and re-signed by authorized prescriber at least annually or when ACIP recommendations change
• Community feedback mechanisms (surveys, hotline, social media monitoring) operational and reviewed weekly
• Multi-language materials available at sites serving linguistically diverse populations
• Staff-to-vaccinee ratio meets throughput targets without compromising screening or observation quality
• Data reconciliation between site-level counts and IIS entries performed within 48 hours of each session

Guidelines

• Never administer a vaccine that has been exposed to temperatures outside the manufacturer's specified range without first consulting the manufacturer or CDC/state immunization program. Viability determinations must be documented.
• Multi-dose vials have strict beyond-use dates (BUD) once punctured. For most vaccines, BUD = 28 days unless manufacturer specifies otherwise. Label every punctured vial with date and time of first use.
• Vaccine confidence is a campaign-critical asset. Train all staff in motivational interviewing techniques for addressing hesitancy. Never dismiss concerns — acknowledge, provide evidence, and offer follow-up.
• For equity-focused campaigns, co-design strategies with community partners. Health departments should not unilaterally decide what "equitable access" means for communities they serve.
• Report all vaccination errors (wrong product, wrong dose, wrong route, expired product) even if no adverse event occurs. Error reporting improves system safety.
• Maintain a real-time vaccine inventory dashboard. Overstocking leads to wastage from expiration; understocking leads to missed appointments and eroded trust.
• Escalate to medical director or state immunization program when: anaphylaxis occurs at a vaccination site, a temperature excursion affects > 50 doses, coverage in any demographic subgroup falls below 50% of the target, or a new safety signal emerges from V-safe or VAERS data.